Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOMIC-Meso Phase 2/3 Study of ADI-PEG 20 with Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma
2015-004281-28Phase 2Unknown
- Sponsor
- Polaris Pharmaceuticals
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma comparing ADI-PEG 20 + pemetrexed + cisplatin with Placebo + pemetrexed + cisplatin (2 arms). Primary endpoints: Tumor response rate (Phase 2) and Overall survival (Phase 3). Status: unknown.
02
Drugs
Pegargiminase
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2015-004281-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004281-28.